Calidi Biotherapeutics, Inc. (CLDI) — Institutional Holders, Q2 2026
23 institutional investment managers reported a CLDI position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $89.3K. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
CLDI in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- GEODE CAPITAL MANAGEMENTAdded · +51,531 sh+$8.8K
- Independent Advisor AllianceNew · +45,000 sh+$7.7K
- Private Advisor GroupNew · +30,000 sh+$5.1K
- JANE STREET GROUPAdded · +19,472 sh+$3.3K
- RFG AdvisoryNew · +12,000 sh+$2.0K
Biggest sellers
- ARMISTICE CAPITALSold out · -879,000 sh-$149.4K
- SABBY MANAGEMENTSold out · -434,903 sh-$73.9K
- Warberg Asset ManagementSold out · -250,000 sh-$42.5K
- Virtu FinancialSold out · -75,769 sh-$12.9K
- HRT FINANCIALSold out · -10,133 sh-$1.7K
CLDI 13F holders ranked 1–23 of 23
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT#1 · 114,550 sh | 114,550 | $19.5K | 0.00% | +81.8% |
| 2 | HighTower Advisors#2 · 83,523 sh | 83,523 | $14.2K | 0.00% | 0.0% |
| 3 | JANE STREET GROUP#3 · 54,274 sh | 54,274 | $9.2K | 0.00% | +56.0% |
| 4 | Independent Advisor Alliance#4 · 45,000 sh | 45,000 | $7.7K | <0.01% | New |
| 5 | RS CRUM#5 · 43,239 sh | 43,239 | $7.4K | — | +7.4% |
| 6 | SRS Capital Advisors#6 · 37,345 sh | 37,345 | $6.3K | 0.00% | 0.0% |
| 7 | Private Advisor Group#7 · 30,000 sh | 30,000 | $5.1K | 0.00% | New |
| 8 | VANGUARD CAPITAL MANAGEMENT#8 · 25,509 sh | 25,509 | $4.3K | 0.00% | 0.0% |
| 9 | Belpointe Asset Management#9 · 19,921 sh | 19,921 | $3.4K | <0.01% | 0.0% |
| 10 | NORTHERN#10 · 17,758 sh | 17,758 | $3.0K | 0.00% | 0.0% |
| 11 | MORGAN STANLEY#11 · 13,244 sh | 13,244 | $2.3K | 0.00% | +39.9% |
| 12 | RFG Advisory#12 · 12,000 sh | 12,000 | $2.0K | 0.00% | New |
| 13 | Farther Finance Advisors#13 · 10,000 sh | 10,000 | $1.7K | — | 0.0% |
| 14 | UBS Group AG#14 · 7,882 sh | 7,882 | $1.3K | 0.00% | New |
| 15 | CITIGROUP#15 · 4,594 sh | 4,594 | $781.00 | 0.00% | New |
| 16 | OSAIC#16 · 2,650 sh | 2,650 | $450.00 | 0.00% | +25.8% |
| 17 | Tower Research Capital (TRC)#17 · 1,396 sh | 1,396 | $237.00 | 0.00% | 0.0% |
| 18 | Finepoint Capital#18 · 1,042 sh | 1,042 | $177.00 | 0.00% | 0.0% |
| 19 | HIGHBRIDGE CAPITAL MANAGEMENT#19 · 1,042 sh | 1,042 | $177.00 | 0.00% | 0.0% |
| 20 | SBI Securities , Ltd.#20 · 375 sh | 375 | $64.00 | — | +226.1% |
| 21 | Tradewinds Capital Management#21 · 101 sh | 101 | $18.00 | — | 0.0% |
| 22 | Reyes Financial Architecture#22 · 100 sh | 100 | $17.00 | — | 0.0% |
| 23 | EVERMAY WEALTH MANAGEMENT#23 · 1 sh | 1 | $1.00 | 0.00% | 0.0% |
Funds that sold out of CLDI in Q2 2026 (9)
Held CLDI at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| ARMISTICE CAPITAL879,000 sh | 879,000 | $209.9K |
| SABBY MANAGEMENT434,903 sh | 434,903 | $103.9K |
| Warberg Asset Management250,000 sh | 250,000 | $59.5K |
| Virtu Financial75,769 sh | 75,769 | $18.0K |
| VANGUARD FIDUCIARY9,219 sh | 9,219 | $2.2K |
| HRT FINANCIAL10,133 sh | 10,133 | $2.0K |
| Apollo Management , L.P.1,042 sh | 1,042 | $249.00 |
| FMR255 sh | 255 | $61.00 |
| CVA Family Office42 sh | 42 | $10.00 |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.